China gives go ahead for new tumor-targeting drug
InnoCare Pharma Ltd, a Hong Kong-listed Chinese mainland biotech company, said on Thursday that its cancer drug Zurletrectinib has won approval from the National Medical Products Administration to treat adults and adolescents aged 12 and older with solid tumors carrying NTRK gene fusions. The therapy, also known as ICP-723, is a next-generation TRK inhibitor designed to…









